Personalized Gonadotropin Microdosing Pen Market Global Report 2026

The personalized gonadotropin microdosing pen market size has grown rapidly in recent years. It will grow from $1.28 billion in 2025 to $1.43 billion in 2026 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to rising infertility rates, increasing use of in vitro fertilization procedures, growing awareness of assisted reproductive treatment options, expanding access to fertility clinics, and increasing patient preference for self-administered injection therapies.

The personalized gonadotropin microdosing pen market size is expected to see rapid growth in the next few years. It will grow to $2.2 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to growing demand for personalized fertility treatment regimens, increasing adoption of reusable injection devices, rising emphasis on treatment adherence and patient compliance, expanding use of fertility preservation procedures, and increasing investment in reproductive healthcare services. Major trends in the forecast period include growing adoption of personalized hormone dosing protocols, increasing demand for fertility devices designed for patient self-administration, rising preference for precise microdosing in fertility treatments, expanding home-based fertility injection programs, and increasing focus on minimizing hormone dosing errors.

The increasing participation of women in the workforce is expected to propel the growth of the personalized gonadotropin microdosing pen market going forward. Female workforce participation refers to the increasing involvement of women in paid employment, professional careers, and income-generating economic activities across various industries. Female workforce participation is increasing due to greater access to higher education and professional skill development opportunities among women. Improved educational attainment enables more women to pursue career advancement, which can contribute to delayed family planning and greater reliance on fertility treatments. Personalized gonadotropin microdosing pens support working women by providing precise, convenient, and user-friendly fertility medication administration, enabling effective fertility management alongside demanding professional schedules. For instance, in March 2024, according to the International Labour Organization, a Switzerland-based United Nations agency focused on labor standards and employment conditions, the employment-to-population ratio for women across G20 countries increased from 46.3% in 2022 to 46.4% in 2023, reflecting continued growth in women's workforce participation. Therefore, the increasing female workforce participation is driving the growth of the personalized gonadotropin microdosing pen market.

Leading companies operating in the personalized gonadotropin microdosing pen market are concentrating on developing individualized dosing algorithms, such as body weight and hormone biomarker-based dose calculation, to strengthen precision in ovarian stimulation protocols and minimize variability in patient response. Body weight and hormone biomarker-based dose calculation is a personalized medication dosing approach in which the amount of a drug is determined according to a patient’s body weight and specific hormone biomarker levels, such as anti-Müllerian hormone (AMH), to optimize treatment effectiveness and minimize the risk of side effects. For example, in May 2024, Ferring Pharmaceuticals, a Switzerland-based specialty biopharmaceutical company, received approval from China’s National Medical Products Administration for Rekovelle, its follitropin delta pen-based gonadotropin therapy, to support personalized ovarian stimulation protocols and improve precision dosing in assisted reproductive technology (ART) treatments. Rekovelle uses an individualized dosing regimen based on a woman’s anti-Müllerian hormone level and body weight, while China represents an important market given an estimated infertility rate of up to 18% associated with delayed marriage and childbirth.

In July 2025, Organon, a US-based women's healthcare company, acquired the MSD Biotech production site in Oss, Netherlands, for an undisclosed amount. Through this acquisition, Organon aims to enhance its fertility treatment manufacturing capabilities, expand its fertility business operations, and maintain the reliable global supply of high-quality fertility products. The transaction includes all fertility-related activities and associated support functions, with the Oss site producing drug substances for two fertility products. MSD Biotech Oss is a Netherlands-based biotechnology manufacturing facility that specializes in producing recombinant fertility drug substances for fertility treatment products, including recombinant follicle-stimulating hormone (FSH) therapies used in assisted reproductive technology and IVF treatments.

Major companies operating in the personalized gonadotropin microdosing pen market are Becton Dickinson and Company, Merck KGaA, Organon & Co., Gerresheimer AG, Ferring Pharmaceuticals A/S, Gedeon Richter Plc., Bharat Serums and Vaccines Limited, Stevanato Group, IBSA Institut Biochimique SA, Ypsomed Holding AG, SHL Medical AG, medmix AG, Theramex HQ UK Limited, Nemera Development S.A.S., Owen Mumford Ltd., CinnaGen Co.

North America was the dominant region in the personalized gonadotropin microdosing pen market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the personalized gonadotropin microdosing pen market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the personalized gonadotropin microdosing pen market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.